Skip to main content
OpenTrials
Completed

NCT Number: NCT03026790

Veterans' Pain Care Organizational Improvement Comparative Effectiveness Study

Background and significance: Treatment with opioid pain medications (like hydrocodone and morphine) is common for severe pain, but studies show these medications may not always help and can cause serious problems. High daily doses of opioids can be especially unsafe. To help patients with chronic pain have better quality of life and avoid medication toxicity, health care teams need to manage pain while helping patients reduce opioid medication doses to safer levels.

Completed

Looking for future studies?

Notify Me

Key information

Age range

21 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Minneapolis VA Health Care System

Minneapolis, Minnesota, 55417, United States

About this study

Study aims: This study will test which of two pain treatment strategies is better for managing pain and helping patients improve safety of opioid medication. For patients on high opioid doses who want to reduce, this study will also test whether offering an extra option for tapering (buprenorphine-naloxone) helps them succeed. Finally, the study will examine patients' and clinicians' experiences with the interventions.

Study description: The study will compare two treatment strategies among patients with pain who are taking long-term opioid pain medications prescribed by VA healthcare facilities across the country. Patients who wish to enter the study will be assigned by chance to telecare collaborative management (TCM) or integrated pain team (IPT). TCM involves a pharmacist and supervising physician working together to find the best medication options for each individual patient. In IPT, a team of clinicians focuses on non-medication pain management options, in addition to pain medication.

All participants will be asked to stay in the study for 12 months. Patients for whom it would be unsafe to participate will not be invited to join. With either treatment strategy, TCM or IPT, participants will have individualized pain care tailored to their needs and preferences. Participants on high opioid medication doses who want to reduce their opioid medication dose will be assigned by chance to get either a regular step-wise taper or a choice between a regular taper or switching to a different medication (buprenorphine-naloxone).

At the end of the study, the two treatment strategies will be compared to see which worked better to (1) decrease pain severity and (2) reduce opioid medication dose. Other outcomes important to patients will also be tracked. These include quality of life, sleep, fatigue, depression, anxiety, and side effects.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Moderate or high-dose long-term opioid therapy (≥ 20 ME mg daily for at least 3 months) for chronic pain
  • Chronic pain of at least moderate severity (defined as pain that is present every or nearly every day for ≥ 6 months and with a score on the PEG 3-item pain measure of ≥ 5)

Exclusion criteria

  • Dementia diagnosis
  • Unstable or severe untreated psychiatric disorder, including severe untreated substance use disorder or active suicidal ideation
  • Unstable or end-stage medical disease that would interfere with participation, including cancer requiring active treatment and life expectancy < 12 months
  • Documentation of suspected controlled substance diversion
  • Inability to communicate by telephone

Treatment and study plan

Medication management

Other

Individualized management of medications for pain

Non-pharmacological pain management

Other

Individualized management of non-medication pain treatment approaches

Buprenorphine-Naloxone

Drug

Option of using buprenorphine-naloxone to assist with opioid dose reduction or discontinuation

Primary outcomes

  1. Pain Response

    Time frame: 12 months

    Binary response variable defined by reduction of at least 30% in Brief Pain Inventory (BPI) total score from baseline

Secondary outcomes

  1. 50% Reduction in Opioid Daily Dose

    Time frame: 12 months

    Binary response variable defined by reduction of at least 50% in opioid daily dose (morphine-equivalent mg) from baseline

  2. Composite Response

    Time frame: 12 months

    Binary composite response variable defined by achieving at least a 30% reduction in BPI total score and at least 50% reduction in opioid daily dose from baseline.

  3. Brief Pain Inventory (BPI) Total Score

    Time frame: 12 months

    Brief Pain Inventory (BPI) total score calculated as average of 11 items (range 0-10; higher is worse)

Other outcomes

  1. VR-12 Physical Component Score

    Time frame: 12 months

    Veterans RAND 12-item health survey (VR-12) Physical Component Score (range 0-100; higher is better)

  2. Symptom Checklist

    Time frame: 12 months

    Medication-related adverse symptoms count (0-19; higher is worse)

  3. PODS Problems

    Time frame: 12 months

    Prescribed Opioids Difficulty Scale (PODS) Problems score (range 0-32; higher is worse)

  4. PHQ-8

    Time frame: 12 months

    Patient Health Questionnaire 8-item (PHQ-8) depression scale score (range 0-24; higher is worse)

  5. GAD-7

    Time frame: 12 months

    General Anxiety Disorders 7-item questionnaire (GAD-7) score (range 0-21; higher is worse)

  6. PROMIS Sleep Disturbance

    Time frame: 12 months

    Patient Reported Outcomes Measurement Information System (PROMIS) sleep disturbance short-form 4a T-score (higher is worse). Raw scores were rescaled into standardized T-scores with a mean of 50 representing the average for the US population and a standard deviation (SD) of 10. A person with a T-score of 40 is one SD below the mean.

  7. PROMIS Fatigue

    Time frame: 12 months

    Patient Reported Outcomes Measurement Information System (PROMIS) fatigue short-form 4a T-score (higher is worse). Raw scores were rescaled into standardized T-scores with a mean of 50 representing the average for the US population and a standard deviation (SD) of 10. A person with a T-score of 40 is one SD below the mean.

  8. Headache Impact Test

    Time frame: 12 months

    Headache Impact Test score (range 36-78; higher is worse)

  9. VR-12 Mental Component Score

    Time frame: 12 months

    Veterans RAND 12-item health survey (VR-12) Mental Component Score (range 0-100; higher is better)

  10. PODS Concerns

    Time frame: 12 months

    Prescribed Opioids Difficulty Scale (PODS) Concerns score (range 0-28; higher is worse)

Sponsors and collaborators

Lead sponsor

University of Minnesota

Other

Collaborators

  • Patient-Centered Outcomes Research Institute

Registry information

Official study title

Comparative Effectiveness of Patient-Centered Strategies to Improve Pain Management and Opioid Safety for Veterans

Acronym: VOICE

Important dates

Study start
2017
Primary completion
2022
Study completion
2022
First posted
Jan 20, 2017
Registry last updated
Jun 5, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.